References
- McElwain T J, Powlas P L. High-dose intravenous melphalan for plasma cell myeloma. Lancet 1983; 2: 822–824
- Selby P J, McElwain T J, Nandi A C. Multiple myeloma treated with high-dose intravenous melphalan. Br J Haematol 1987; 65: 55–62
- Case D C, Coleman M, Gottlieb A. Phase I-D trial of high-dose melphalan in previously untreated and stage III multiple myeloma: Cancer and Leukemia Group B Study 8512. Clin Invest, in press
- Petrucci M T, Avisati G, Tribalto M. Intermediate dose (25 mg/m2) intravenous melphalan with multiple myeloma in relapse or refractory to standard treatment. Eur J Haematol 1989; 42: 233
- Brenning G, Ahre A, Nilsson K. Correlation between in vitro and in vivo sensitivity in human leukocyte interferon in patients with multiple myeloma. Scand J Haematol 1985; 25: 543–549
- Lichtman S, Ratain M, Budman D R. Phase I trial of recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) plus high dose cyclophosphamide (CYC) in solid tumors. ASCO Proc 1990; 66, Abstr K256
- Oken M M, Kyle R A, Greipp P R. Complete remission (CR) induction with VBMCP + interferon (rIFN 2) in multiple myeloma: Three year follow up. Proc ASCO 1989; 8: 272, Abstr 1062
- Mellstedt H, Bjorkholm M, Bjoreman M. MP vesus MP/IFN-induction chemotherapy: A randomized trial in multiple myeloma (abstr). IFN-Therapy in B Cell Malignancies. V. Hanover Interferon Workshop. Feb 21–23, 1990; 44